GS: "Will RECAF test positive for the other cancers where CA 125 is elevated? How is the combination going to pinpoint ovarian cancer?"
I don't know the details. You would need to read the ISOBM poster and publications, when they become available, to see exactly what Moro included as positives and negatives.
However, a few points:
You asserted that it is not possible to combine two non-specific tests to get a more specific test. This is possible, and it is the basis for the proteomic and genomic tests about which you are always extremely positive, in contrast to RECAF, about which you are always negative.
You are the one who asserts repeatedly that no 'universal' marker will ever be adopted. I don't agree with this. Knowing cancer is present at an early stage would be a big step forward IMO. There are other techniques that can then be used to determine where the cancer is, once you know it is there. Even if RECAF does not pinpoint the location of cancer, it can still be extremely valuable IMO.
The reason for presenting publications (including posters) at conferences is to subject the work to peer review. The fact that Moro's work is being presented at ISOBM gives one some assurance that it is technically correct and novel. You are criticizing the RECAF/CA-125 work already, without even knowing the details. I put more trust in the ISOBM peer review process than your speculations.
